Response of antibody titers to SARS-CoV-2 vaccination and clinical outcomes during the predominance of the Omicron variant in Colombia

© The Author(s) 2023..

Introduction: The response to vaccination against the virus that causes severe acute respiratory infection syndrome coronavirus 2 is lower in renal transplant recipients than in the general population. The data obtained from Latin America showed reduced immunogenicity under inactivated virus vaccination schedules and messenger ribonucleic acid platforms.

Methods: A retrospective cohort study including renal transplant recipients from Colombia with a two-dose vaccination schedule against severe acute respiratory infection syndrome coronavirus 2 with Pfizer, AstraZeneca, Moderna, Jansen, and Sinovac vaccines between March 1, 2021 and December 1, 2021, was carried out with a follow-up period to evaluate outcomes until May 2022. The outcomes correspond to the titers of immunoglobulin G antibodies against the receptor binding domain of the severe acute respiratory infection syndrome coronavirus 2 spike and a composite outcome of mortality, general, and intensive care unit hospitalization.

Results: In total, 215 renal transplant recipients with two doses of vaccination for severe acute respiratory infection syndrome coronavirus 2 during the predominance of the Omicron variant in Colombia were included, with the measurement of immunoglobulin G antibody titers against the receptor binding domain of the severe acute respiratory infection syndrome coronavirus 2 spike at 8 weeks of vaccination. The mean age was 52.1 years, and the standard deviation was ± 14.2; severe acute respiratory infection syndrome coronavirus 2 infection occurred in 20% of the population, of which 23.26% required hospitalization, 13.95% were under intensive care unit management, and four cases of mortality (9.3%) were reported. Of the total population, 52.5% had antibody titers higher than 0.8 IU/mL (median 0.77 IU/mL, interquartile range 0.4-131). Patients with severe acute respiratory infection syndrome coronavirus 2 infection had a median antibody titer of 0.4 IU/mL (interquartile range 0.4-3.45), and those without infection had a median antibody titer of 1.8 IU/mL (interquartile range 0.4-202) (p = 0.015).

Conclusion: Anti-severe acute respiratory infection syndrome coronavirus 2 antibody titers with a cutoff point less than 0.8 IU/mL are associated with increased risk of severe acute respiratory infection syndrome coronavirus 2 infection.

Medienart:	E-Artikel

Erscheinungsjahr:	2023
Erschienen:	2023

Enthalten in:	Zur Gesamtaufnahme - volume:11
Enthalten in:	SAGE open medicine - 11(2023) vom: 07., Seite 20503121231187754

Sprache:	Englisch

Beteiligte Personen:	Montero, Camilo [VerfasserIn] Torres, Rodolfo [VerfasserIn] Reina, Maricely [VerfasserIn] Flechas, Jonth [VerfasserIn] Andrade, David [VerfasserIn] Moreno, Sebastián [VerfasserIn] Granados, Camila [VerfasserIn] Yomayusa, Nancy [VerfasserIn]

Links:	Volltext

Themen:	COVID-19 vaccines Immunology Journal Article Kidney transplantation SARS-CoV-2

Anmerkungen:	Date Revised 26.07.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE

doi:	10.1177/20503121231187754

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	NLM359893457